Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 69,076 |
|
|||||
| News | (1) | ||||||
| Day High | 21.8697 | Low High |
|||||
| Day Low | 19.12 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Pharvaris NV | PHVS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.63 | 3.22% | 20.18 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 19.79 | 19.12 | 21.8697 | 20.18 | 19.55 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,403 | 69,076 | $ 20.64 | $ 1,425,676 | - | 8.20 - 33.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:24:48 | 1 | $ 19.91 | USD |
Pharvaris NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 837.28M | 40.82M | - | 0 | -100.88M | -2.47 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Pharvaris NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PHVS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 21.70 | 21.8697 | 19.12 | 20.11 | 103,486 | -1.52 | -7.00% |
| 1 Month | 22.56 | 25.50 | 19.12 | 21.82 | 65,144 | -2.38 | -10.55% |
| 3 Months | 23.10 | 27.464 | 17.57 | 22.40 | 73,970 | -2.92 | -12.64% |
| 6 Months | 16.43 | 33.00 | 16.20 | 25.57 | 120,657 | 3.75 | 22.82% |
| 1 Year | 8.68 | 33.00 | 8.20 | 22.90 | 86,974 | 11.50 | 132.49% |
| 3 Years | 20.50 | 33.00 | 1.77 | 12.66 | 192,035 | -0.32 | -1.56% |
| 5 Years | 25.00 | 42.86 | 1.77 | 13.53 | 183,835 | -4.82 | -19.28% |
Pharvaris NV Description
| Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. |
